{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:30:49Z","timestamp":1759177849334,"version":"3.37.3"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":271,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1111\/ijcp.12584","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T23:44:36Z","timestamp":1417823076000},"page":"588-596","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes and resource use after 24\u00a0months of insulin therapy in Turkish patients with type 2 diabetes: subgroup analysis of the TREAT study"],"prefix":"10.1155","volume":"69","author":[{"given":"A.","family":"Oguz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine; Istanbul Medeniyet University G\u00f6ztepe Training and Research Hospital; Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cevizci","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Okmeydani Training and Research Hospital; Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ertekin","sequence":"additional","affiliation":[{"name":"Lilly \u0130la\u00e7 Ticaret Ltd.; Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Abdulnabi","sequence":"additional","affiliation":[{"name":"InVentiv Health Clinical; Ann Arbor MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Turkish TREAT Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,4]]},"reference":[{"key":"10.1111\/ijcp.12584-BIB0001|ijcp12584-cit-0001","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2337\/diacare.25.9.1551","article-title":"Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP)","volume":"25","author":"Satman","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0002|ijcp12584-cit-0002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10654-013-9771-5","article-title":"Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults","volume":"28","author":"Satman","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"10.1111\/ijcp.12584-BIB0003|ijcp12584-cit-0003","first-page":"314","article-title":"Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey","volume":"6","author":"Onat","year":"2006","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1111\/ijcp.12584-BIB0004|ijcp12584-cit-0004","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ndt\/gfq656","article-title":"A population-based survey of Chronic REnal Disease In Turkey - the CREDIT study","volume":"26","author":"Suleymanlar","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ijcp.12584-BIB0005|ijcp12584-cit-0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-8603-9-16","article-title":"Management of diabetes and diabetes policies in Turkey","volume":"9","author":"Tatar","year":"2013","journal-title":"Global Health"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12584-BIB0006|ijcp12584-cit-0006","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8227(01)00304-7","article-title":"The cost of diabetes and diabetes care","volume":"54","author":"Bjork","year":"2001","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1111\/ijcp.12584-BIB0007|ijcp12584-cit-0007","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2337\/diacare.20.12.1847","article-title":"The cost to health plans of poor glycemic control","volume":"20","author":"Gilmer","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0008|ijcp12584-cit-0008","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.285.2.182","article-title":"Effect of improved glycemic control on health care costs and utilization","volume":"285","author":"Wagner","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/ijcp.12584-BIB0009|ijcp12584-cit-0009","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s00125-002-0859-9","article-title":"Assessing the impact of complications on the costs of Type II diabetes","volume":"45","author":"Williams","year":"2002","journal-title":"Diabetologia"},{"key":"10.1111\/ijcp.12584-BIB0010|ijcp12584-cit-0010","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"volume-title":"Global Guideline for Type 2 Diabetes","year":"2005","author":"IDF Clinical Guidelines Task Force","key":"10.1111\/ijcp.12584-BIB0011|ijcp12584-cit-0011"},{"key":"10.1111\/ijcp.12584-BIB0012|ijcp12584-cit-0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18553\/jmcp.2003.9.4.309","article-title":"Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus","volume":"9","author":"Rosenblum","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/ijcp.12584-BIB0013|ijcp12584-cit-0013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11606-007-0139-y","article-title":"Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy","volume":"22","author":"Nichols","year":"2007","journal-title":"J Gen Intern Med"},{"key":"10.1111\/ijcp.12584-BIB0014|ijcp12584-cit-0014","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1464-5491.2007.02279.x","article-title":"Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK","volume":"24","author":"Rubino","year":"2007","journal-title":"Diabet Med"},{"key":"10.1111\/ijcp.12584-BIB0015|ijcp12584-cit-0015","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-2006-951779","article-title":"Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study","volume":"114","author":"Simons","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1111\/ijcp.12584-BIB0016|ijcp12584-cit-0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1472-6823-9-19","article-title":"The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study","volume":"9","author":"Goodall","year":"2009","journal-title":"BMC Endocr Disord"},{"key":"10.1111\/ijcp.12584-BIB0017|ijcp12584-cit-0017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2337\/dc11-1171","article-title":"Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes","volume":"35","author":"Nichols","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0018|ijcp12584-cit-0018","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/03007995.2013.803053","article-title":"Clinical outcomes after 24\u00a0months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study","volume":"29","author":"Oguz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/ijcp.12584-BIB0019|ijcp12584-cit-0019","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3111\/13696998.2013.812040","article-title":"Evaluation of insulin initiation on resource utilization and direct costs of treatment over 12\u00a0months in patients with type 2 diabetes in Europe: results from INSTIGATE and TREAT observational studies","volume":"16","author":"Brismar","year":"2013","journal-title":"J Med Econ"},{"key":"10.1111\/ijcp.12584-BIB0020|ijcp12584-cit-0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1111\/ijcp.12584-BIB0021|ijcp12584-cit-0021","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1345\/aph.1D612","article-title":"Medication adherence and associated hemoglobin A1c in type 2 diabetes","volume":"38","author":"Krapek","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1111\/ijcp.12584-BIB0022|ijcp12584-cit-0022","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1464-5491.2009.02898.x","article-title":"Measurements of medication adherence in diabetic patients with poorly controlled HbA(1c)","volume":"27","author":"Cohen","year":"2010","journal-title":"Diabet Med"},{"key":"10.1111\/ijcp.12584-BIB0023|ijcp12584-cit-0023","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1464-5491.2000.00322.x","article-title":"Adaptation of the Diabetes Health Profile (DHP-1) for use with patients with type 2 diabetes mellitus: psychometric evaluation and cross-cultural comparison","volume":"17","author":"Meadows","year":"2000","journal-title":"Diabet Med"},{"key":"10.1111\/ijcp.12584-BIB0024|ijcp12584-cit-0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12584-BIB0025|ijcp12584-cit-0025","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc09-S013","article-title":"Standards of medical care in diabetes - 2009","volume":"32","author":"American Diabetes Association","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0026|ijcp12584-cit-0026","first-page":"1","article-title":"Clinical practice guidelines for diagnosis, treatment and follow-up of diabetes mellitus and its complications","volume":"14","author":"Satman","year":"2010","journal-title":"Turk J Endocrinol Metabol"},{"key":"10.1111\/ijcp.12584-BIB0027|ijcp12584-cit-0027","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1185\/03007990902739669","article-title":"Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study","volume":"25","author":"Jones","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/ijcp.12584-BIB0028|ijcp12584-cit-0028","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1463-1326.2011.01394.x","article-title":"Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes","volume":"13","author":"Rhoads","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12584-BIB0029|ijcp12584-cit-0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pcd.2010.03.001","article-title":"Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study","volume":"4","author":"Dale","year":"2010","journal-title":"Prim Care Diabetes"},{"key":"10.1111\/ijcp.12584-BIB0030|ijcp12584-cit-0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4158\/EP12269.OR","article-title":"Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice","volume":"19","author":"Caputo","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1111\/ijcp.12584-BIB0031|ijcp12584-cit-0031","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1463-1326.2012.01602.x","article-title":"Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice","volume":"14","author":"Khunti","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12584-BIB0032|ijcp12584-cit-0032","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1742-1241.2008.01917.x","article-title":"The IMPROVE study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts","volume":"62","author":"Valensi","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12584-BIB0033|ijcp12584-cit-0033","first-page":"262","article-title":"Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry","volume":"11","author":"Karter","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1111\/ijcp.12584-BIB0034|ijcp12584-cit-0034","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2337\/dc08-2117","article-title":"DURAbility of basal versus lispro mix 75\/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75\/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes","volume":"32","author":"Buse","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0035|ijcp12584-cit-0035","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s12325-011-0074-5","article-title":"A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens","volume":"28","author":"Xie","year":"2011","journal-title":"Adv Ther"},{"key":"10.1111\/ijcp.12584-BIB0036|ijcp12584-cit-0036","first-page":"50","article-title":"Glycemic control of Turkish adult diabetic patients","volume":"12","author":"Oguz","year":"2008","journal-title":"Turk Jem"},{"key":"10.1111\/ijcp.12584-BIB0037|ijcp12584-cit-0037","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010","volume":"36","author":"Stark Casagrande","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0038|ijcp12584-cit-0038","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12584-BIB0039|ijcp12584-cit-0039","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0040|ijcp12584-cit-0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12584-BIB0041|ijcp12584-cit-0041","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1185\/03007995.2011.555755","article-title":"Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries","volume":"27","author":"Liebl","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/ijcp.12584-BIB0042|ijcp12584-cit-0042","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13300-012-0009-4","article-title":"Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE","volume":"3","author":"Liebl","year":"2012","journal-title":"Diabetes Ther"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12584","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:09:15Z","timestamp":1643350155000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,4]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12584","relation":{},"ISSN":["1368-5031"],"issn-type":[{"type":"print","value":"1368-5031"}],"subject":[],"published":{"date-parts":[[2014,12,4]]},"assertion":[{"value":"2015-02-24","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}